Table 3. Summary of dose-limiting toxicities and serious adverse events.

	Phase I		Phase II
	30 mg/d (n = 3)	20 mg/d (n = 3)	3-h infusion (20 mg/d) (n = 7)	24-h infusion (60 mg/d) (n = 5)
Dose-limiting toxicity	Grade 3 somnolence/confusion (1); grade 3 ataxia (1)	0	0	0
Serious TEAE, n (grade, attribution)
Febrile neutropenia	1 (gr 3, NR)		1 (gr 3, NR)
Atrial fibrillation			2 (gr 3, NR; gr 3, NR)
Acute myocardial infarction			1 (gr 3, NR)	1 (gr 4, PS)
Cough			2 (gr 1, NR; gr 2, PS)
Catheter site infection			1 (gr 3, NR)	1 (gr 3, NR)
Cytokine release syndrome		1 (gr 2, PR)
Pneumonia		1 (gr 3, NR)	1 (gr 3, NR)
Acute sinusitis			1 (gr 1, NR)
Dyspnea			1 (gr 2, NR)
Fatigue				1 (gr 5, NR)
Dizziness				1 (gr 3, PR)

AE, adverse event; DLT, dose-limiting toxicity (DLTs were defined as grade ≥3 infusion-related neurologic AEs and nonhematologic AEs not responsive to symptom-directed therapy); PR, probably related; PS, possibly related; NR, not related; TEAE, treatment-emergent adverse event.